THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Use of a compound comprising a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of an NET mediated ailment; wherein the polyanionic sulfated cellobioside modified with a small uncharged substituent at its reducing terminus, has the general structure of:



wherein, R1 is O-(C_{1-6})alkyl or S-(C_{1-6})alkyl; and R2 to R8 are each a sulfate group; and

wherein, the NET mediated ailment is Gout.

2. The use according to claim 1, wherein R1 is a methoxy or ethoxy group.

3. The use according to any one of claims 1 to 2, wherein the sulfated cellobioside modified with a small uncharged substituent at its reducing terminus is sulfated β-O-methyl cellobioside disaccharide.

4. The use according to any one of claims 1 to 2, wherein the sulfated cellobioside modified with a small uncharged substituent at its reducing terminus is sodium β-O-methyl cellobioside sulfate.

5. The use of any one of claims 1 to 4, wherein;

a) the medicament is effective to reduce, minimize or inhibit NET mediated pathology in the subject; and/or

b) the medicament is effective to reduce, minimize or inhibit NETs that (i) are cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.

6. The use of any one of claims 1 to 5, wherein the medicament is formulated for single dose administration to a subject.

7. The use of any one of claims 1 to 5, wherein the medicament is formulated to be administered to a subject in multiple doses.

8. The use of any one of claims 1 to 7, wherein the medicament is formulated to be administered to a subject, at the same time as, or concomitantly with, a second active agent selected from the group consisting of: an anti-inflammatory agent, an antibiotic agent, an antiviral agent, an antifungal agent or another form of medical intervention as an adjunct treatment for the medical condition or disease being treated.

9. The use of claim 8, wherein the second active agent comprises one or more anti-inflammatory agent(s).

10. The use according to any one of claims 1 to 9, wherein the medicament comprises an aqueous solution of the polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus.

11. The use according to claim 10, wherein the medicament comprises a buffer system.

12. The use according to claims 11, wherein the medicament comprises a phosphate buffer system.

13. The use according to any one of claims 1 to 12, wherein the medicament is formulated with a sufficient amount of a buffer system to provide an initial pH of 7.5.